Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review)
- Authors:
- Seyed Sajjad Babaeimarzangou
- Himasadat Zaker
- Ehsan Soleimannezhadbari
- Naeimeh Shamsi Gamchi
- Masoud Kazeminia
- Shima Tarighi
- Homayon Seyedian
- Aristidis Tsatsakis
- Demetrios A. Spandidos
- Denisa Margina
-
Affiliations: Division of Poultry Health and Diseases, Department of Clinical Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia 5756151818, Iran, Histology and Microscopic Analysis Division, RASTA Specialized Research Institute (RSRI), West Azerbaijan Science and Technology Park (WASTP), Urmia 5756115322, Iran, Young Researchers Club, Urmia Branch, Islamic Azad University, Urmia 5716963896, Iran, Department of Food Hygiene and Quality Control, Faculty of Veterinary Medicine, University of Tehran, Tehran 1417935840, Iran, Veterinary Office of West Azerbaijan Province, Urmia 5717617695, Iran, Faculty of Veterinary Medicine, Urmia University, Urmia 5756151818, Iran, Laboratory of Toxicology, Department of Medicine, University of Crete, 71307 Heraklion, Greece, Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece, Department of Biochemistry, Faculty of Pharmacy, ‘Carol Davila’ University of Medicine and Pharmacy, 020956 Bucharest, Romania - Published online on: November 30, 2022 https://doi.org/10.3892/etm.2022.11741
- Article Number: 42
-
Copyright: © Babaeimarzangou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Du L, Tai W, Zhou Y and Jiang S: Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 15:1123–1134. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hui DSC and Zumla A: Severe acute respiratory syndrome: Historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 33:869–889. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Ramadan N and Shaib H: Middle East respiratory syndrome coronavirus (MERS-CoV): A review. Germs. 9:35–42. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Donnelly CA, Malik MR, Elkholy A, Cauchemez S and Van Kerkhove MD: Worldwide reduction in MERS cases and deaths since 2016. Emerg Infect Dis. 25:1758–1760. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 395:1054–1062. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Folegatti PM, Harrison K, Preciado-Llanes L, Lopez FR, Bittaye M, Kim YC, Flaxman A, Bellamy D, Makinson R, Sheridan J, et al: A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat Commun. 12(4636)2021.PubMed/NCBI View Article : Google Scholar | |
|
Zeller H, Van Bortel W and Sudre B: Chikungunya: Its history in Africa and Asia and its spread to new regions in 2013-2014. J Infect Dis. 214 (Suppl 5):S436–S440. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Bernasconi V, Kristiansen PA, Whelan M, Román RG, Bettis A, Yimer SA, Gurry C, Andersen SR, Yeskey D, Mandi H, et al: Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 63:65–73. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD and Fouchier RA: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 367:1814–1820. 2012.PubMed/NCBI View Article : Google Scholar | |
|
World Health Organization (WHO): ‘MERS situation update, September 2019’. WHO, Geneva, 2019. https://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-september-2019.html. | |
|
Wang C, Zheng X, Gai W, Wong G, Wang H, Jin H, Feng N, Zhao Y, Zhang W, Li N, et al: Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antiviral Res. 140:55–61. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Yu X, Zhang S, Jiang L, Cui Y, Li D, Wang D, Wang N, Fu L, Shi X, Li Z, et al: Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci Rep. 5(13133)2015.PubMed/NCBI View Article : Google Scholar | |
|
Letko M, Marzi A and Munster V: Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 5:562–569. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Li F and Du L: MERS coronavirus: An emerging zoonotic virus. Viruses. 11(663)2019.PubMed/NCBI View Article : Google Scholar | |
|
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A and Li F: Structural basis of receptor recognition by SARS-CoV-2. Nature. 581:221–224. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Woo PCY, Lau SKP, Chen Y, Wong EYM, Chan KH, Chen H, Zhang L, Xia N and Yuen KY: Rapid detection of MERS coronavirus-like viruses in bats: Pote1ntial for tracking MERS coronavirus transmission and animal origin. Emerg Microbes Infect. 7(18)2018.PubMed/NCBI View Article : Google Scholar | |
|
Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, Al Rabeeah AA, Alhakeem RF, Assiri A, Al-Tawfiq JA, et al: Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. mBio. 5:e01062–13. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM and Madani TA: Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 370:2499–2505. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Alshukairi AN, Zheng J, Zhao J, Nehdi A, Baharoon SA, Layqah L, Bokhari A, Al Johani SM, Samman N, Boudjelal M, et al: High prevalence of MERS-CoV infection in camel workers in Saudi Arabia. mBio. 9:e01985–18. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Li E, Chi H, Huang P, Yan F, Zhang Y, Liu C, Wang Z, Li G, Zhang S, Mo R, et al: A novel bacterium-like particle vaccine displaying the MERS-CoV receptor-binding domain induces specific mucosal and systemic immune responses in mice. Viruses. 11(799)2019.PubMed/NCBI View Article : Google Scholar | |
|
Chi H, Zheng X, Wang X, Wang C, Wang H, Gai W, Perlman S, Yang S, Zhao J and Xia X: DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 35:2069–2075. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Al-Amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, Al-Muhanna MK, Alhabbab RY, Azhar EI, Li X and Hashem AM: Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep. 7(44875)2017.PubMed/NCBI View Article : Google Scholar | |
|
Ababneh M, Alrwashdeh M and Khalifeh M: Recombinant adenoviral vaccine encoding the spike 1 subunit of the Middle East respiratory syndrome coronavirus elicits strong humoral and cellular immune responses in mice. Vet World. 12:1554–1562. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Bodmer BS, Fiedler AH, Hanauer JRH, Prüfer S and Mühlebach MD: Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virology. 521:99–107. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Langenmayer MC, Lülf-Averhoff AT, Adam-Neumair S, Fux R, Sutter G and Volz A: Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S. Biologicals. 54:58–62. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Adney DR, Wang L, Van Doremalen N, Shi W, Zhang Y, Kong WP, Miller MR, Bushmaker T, Scott D, de Wit E, et al: Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses. 11(212)2019.PubMed/NCBI View Article : Google Scholar | |
|
Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S, Albrahim R, et al: Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci Rep. 9(16292)2019.PubMed/NCBI View Article : Google Scholar | |
|
Hashem AM, Algaissi A, Agrawal AS, Al-Amri SS, Alhabbab RY, Sohrab SS, S Almasoud A, Alharbi NK, Peng BH, Russell M, et al: A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model. J Infect Dis. 220:1558–1567. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR and Gall JG: Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine. 25:2074–2084. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, et al: ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 35:3780–3788. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Liu R, Wang J, Shao Y, Wang X, Zhang H, Shuai L, Ge J, Wen Z and Bu Z: A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral Res. 150:30–38. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zhou Y, Yang Y, Huang J, Jiang S and Du L: Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. Viruses. 11(60)2019.PubMed/NCBI View Article : Google Scholar | |
|
Agnihothram S, Menachery VD, Yount BL Jr, Lindesmith LC, Scobey T, Whitmore A, Schäfer A, Heise MT and Baric RS: Development of a broadly accessible Venezuelan equine encephalitis virus replicon particle vaccine platform. J Virol. 92:e00027–18. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lan J, Yao Y, Deng Y, Chen H, Lu G, Wang W, Bao L, Deng W, Wei Q, Gao GF, et al: Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EEBioMedicine. 2:1438–1446. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Wang Q, Qi J, Yuan Y, Xuan Y, Han P, Wan Y, Ji W, Li Y, Wu Y, Wang J, et al: Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe. 16:328–337. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Liu RQ, Ge JY, Wang JL, Yu S, Zhang HL, Wang JL, Wen ZY and Bu ZG: Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels. J Integr Agric. 16:2264–2273. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, et al: Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA. 114:E7348–E7357. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB and Schnell MJ: One-health: A safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus. J Virol. 91:e02040–16. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y and Du L: Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J Virol. 91:e01651–16. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Papageorgiou N, Lichière J, Baklouti A, Ferron F, Sévajol M, Canard B and Coutard B: Structural characterization of the N-terminal part of the MERS-CoV nucleocapsid by X-ray diffraction and small-angle X-ray scattering. Acta Crystallogr D Struct Biol. 72:192–202. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zhang L, Li L, Yan L, Ming Z, Jia Z, Lou Z and Rao Z: Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East respiratory syndrome coronavirus. J Virol. 92:e00893–18. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Tang J, Zhang N, Tao X, Zhao G, Guo Y, Tseng CTK, Jiang S, Du L and Zhou Y: Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 11:1244–1250. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, et al: Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 87:9939–9942. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Nyon MP, Du L, Tseng CTK, Seid CA, Pollet J, Naceanceno KS, Agrawal A, Algaissi A, Peng BH, Tai W, et al: Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 36:1853–1862. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Tao X, Garron T, Agrawal AS, Algaissi A, Peng BH, Wakamiya M, Chan TS, Lu L, Du L, Jiang S, et al: Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 90:57–67. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hao W, Wojdyla JA, Zhao R, Han R, Das R, Zlatev I, Manoharan M, Wang M and Cui S: Crystal structure of Middle East respiratory syndrome coronavirus helicase. PLoS Pathog. 13(e1006474)2017.PubMed/NCBI View Article : Google Scholar | |
|
Wang C, Zheng X, Gai W, Zhao Y, Wang H, Wang H, Feng N, Chi H, Qiu B, Li N, et al: MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget. 8:12686–12694. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC and Frieman MB: MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 35:1586–1589. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Glenn GM, Smith GE and Frieman MB: Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 32:3169–3174. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Kato T, Takami Y, Kumar Deo V and Park EY: Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. J Biotechnol. 306:177–184. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Jung SY, Kang KW, Lee EY, Seo DW, Kim HL, Kim H, Kwon T, Park HL, Kim H, Lee SM and Nam JH: Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 36:3468–3476. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Veit S, Jany S, Fux R, Sutter G and Volz A: CD8+ T cells responding to the Middle East respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice. Viruses. 10(718)2018.PubMed/NCBI View Article : Google Scholar | |
|
Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng BH, Couch RB and Tseng CTK: Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 12:2351–2356. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Deng Y, Lan J, Bao L, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C and Tan W: Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 7(60)2018.PubMed/NCBI View Article : Google Scholar | |
|
Scobey T, Yount BL, Sims AC, Donaldson EF, Agnihothram SS, Menachery VD, Graham RL, Swanstrom J, Bove PF, Kim JD, et al: Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci USA. 110:16157–16162. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, et al: Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 19:1013–1022. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, et al: A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 7(301ra132)2015.PubMed/NCBI View Article : Google Scholar | |
|
Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, et al: Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: An open-label, phase 1 trial. Lancet Infect Dis. 20:827–838. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, Gale MJ Jr, Baric RS, Enjuanes L, Gallagher T, et al: Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA. 111:4970–4975. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, et al: Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 20:816–826. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Bosaeed M, Balkhy HH, Almaziad S, Aljami HA, Alhatmi H, Alanazi H, Alahmadi M, Jawhary A, Alenazi MW, Almasoud A, et al: Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Lancet Microbe. 3:e11–e20. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Dolzhikova IV, Grousova DM, Zubkova OV, Tukhvatulin AI, Kovyrshina AV, Lubenets NL, Ozharovskaia TA, Popova O, Esmagambetov IB, Shcheblyakov DV, et al: Preclinical studies of immunogenity, protectivity, and safety of the combined vector vaccine for prevention of the Middle East respiratory syndrome. Acta Naturae. 12:114–123. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chan JFW, Lau SKP and Woo PCY: The emerging novel Middle East respiratory syndrome coronavirus: the ‘knowns’ and ‘unknowns’. J Formos Med Assoc. 112:372–381. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Du L, He Y, Zhou Y, Liu S, Zheng BJ and Jiang S: The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol. 7:226–236. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Peiris JS, Guan Y and Yuen KY: Severe acute respiratory syndrome. Nat Med. 10 (12 Suppl):S88–S97. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B, Zhang W, Peng C, et al: Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 503:535–538. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T and Baric R: Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 133:45–62. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Ithete NL, Stoffberg S, Corman VM, Cottontail VM, Richards LR, Schoeman MC, Drosten C, Drexler JF and Preiser W: Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis. 19:1697–1699. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Minor PD: Live attenuated vaccines: Historical successes and current challenges. Virology. 479:379–392. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R, Enjuanes L and Subbarao K: A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol. 82:7721–7724. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, Rocchi P and Ng WL: Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell. 79:710–727. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR and Baric RS: A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med. 18:1820–1826. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Menachery VD, Gralinski LE, Mitchell HD, Dinnon KH III, Leist SR, Yount BL Jr, Graham RL, McAnarney ET, Stratton KG, Cockrell AS, et al: Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis. mSphere. 2:e00346–17. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Stauffer F, El-Bacha T and Da Poian AT: Advances in the development of inactivated virus vaccines. Recent Pat Antiinfect Drug Discov. 1:291–296. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Escriou N, Callendret B, Lorin V, Combredet C, Marianneau P, Février M and Tangy F: Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology. 452:32–41. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Zuñiga S, Pascual-Iglesias A, Sanchez CM, Sola I and Enjuanes L: Virulence factors in porcine coronaviruses and vaccine design. Virus Res. 226:142–151. 2016.PubMed/NCBI View Article : Google Scholar | |
|
DeDiego ML, Alvarez E, Almazán F, Rejas MT, Lamirande E, Roberts A, Shieh WJ, Zaki SR, Subbarao K and Enjuanes L: A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 81:1701–1713. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K and Collins PL: Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 363:2122–2127. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Qin E, Shi H, Tang L, Wang C, Chang G, Ding Z, Zhao K, Wang J, Chen Z, Yu M, et al: Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine. 24:1028–1034. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ and Couch RB: Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 7(e35421)2012.PubMed/NCBI View Article : Google Scholar | |
|
Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H and Nagata N: Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. 88:8597–8614. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Chang CY, Hong WWL, Chong P and Wu SC: Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development. Vaccine. 24:1132–1141. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Feng Y, Wan M, Wang XJ, Zhang PY, Yu YL and Wang LY: Expression of predicted B cell epitope peptide in S2 subunit of SARS coronavirus spike protein in E. coli and identification of its mimic antigenicity. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 23:113–116. 2007.PubMed/NCBI(In Chinese). | |
|
Li J, Ulitzky L, Silberstein E, Taylor DR and Viscidi R: Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Viral Immunol. 26:126–132. 2013.PubMed/NCBI View Article : Google Scholar | |
|
He Y, Li J, Heck S, Lustigman S and Jiang S: Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design. J Virol. 80:5757–5767. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y, Zheng BJ and Jiang S: A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 23:211–219. 2010.PubMed/NCBI View Article : Google Scholar | |
|
He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M and Jiang S: Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine. Biochem Biophys Res Commun. 324:773–781. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Liu RY, Wu LZ, Huang BJ, Huang JL, Zhang YL, Ke ML, Wang JM, Tan WP, Zhang RH, Chen HK, et al: Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res. 112:24–31. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Wang N, Shang J, Jiang S and Du L: Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 11(298)2020.PubMed/NCBI View Article : Google Scholar | |
|
Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K and Collins PL: Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA. 101:9804–9809. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Li YD, Chi WY, Su JH, Ferrall L, Hung CF and Wu TC: Coronavirus vaccine development: From SARS and MERS to COVID-19. J Biomed Sci. 27(104)2020.PubMed/NCBI View Article : Google Scholar | |
|
Bouard D, Alazard-Dany N and Cosset FL: Viral vectors: From virology to transgene expression. Br J Pharmacol. 157:153–165. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S and Gambotto A: Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 362:1895–1896. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Kobinger GP, Figueredo JM, Rowe T, Zhi Y, Gao G, Sanmiguel JC, Bell P, Wivel NA, Zitzow LA, Flieder DB, et al: Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine. 25:5220–5231. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Zhang CH, Lu JH, Wang YF, Zheng HY, Xiong S, Zhang MY, Liu XJ, Li JX, Wan ZY, Yan XG, et al: Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain. Vaccine. 23:3196–3201. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K and Moss B: Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA. 101:6641–6646. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, et al: Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 79:2678–2688. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, et al: Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 78:12672–12676. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Czub M, Weingartl H, Czub S, He R and Cao J: Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 23:2273–2279. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, et al: Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3(e525)2006.PubMed/NCBI View Article : Google Scholar | |
|
Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K and Roberts A: Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology. 340:174–182. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Lokugamage KG, Yoshikawa-Iwata N, Ito N, Watts DM, Wyde PR, Wang N, Newman P, Kent Tseng CT, Peters C and Makino S: Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine. 26:797–808. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K and Nabel GJ: A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 428:561–564. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, et al: A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine. 26:6338–6343. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Lin J, Zhang JS, Su N, Xu JG, Wang N, Chen JT, Chen X, Liu YX, Gao H, Jia YP, et al: Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 12:1107–1113. 2007.PubMed/NCBI | |
|
Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H, Cheng X, Wang C, Chang G, Zhu Q, et al: Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 23:391–394. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Leta S, Beyene TJ, De Clercq EM, Amenu K, Kraemer MUG and Revie CW: Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus. Int J Infect Dis. 67:25–35. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Vega-Rúa A, Zouache K, Girod R, Failloux AB and Lourenço-de-Oliveira R: High level of vector competence of Aedes aegypti and Aedes albopictus from ten American countries as a crucial factor in the spread of chikungunya virus. J Virol. 88:6294–6306. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Harrison VR, Binn LN and Randall R: Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am J Trop Med Hyg. 16:786–791. 1967.PubMed/NCBI | |
|
Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J, Vijayachari P, Sundaram SG, et al: A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis. 5(e928)2011.PubMed/NCBI View Article : Google Scholar | |
|
Tretyakova I, Hearn J, Wang E, Weaver S and Pushko P: DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis. 209:1882–1890. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, Frolov I and Weaver SC: Chimeric alphavirus vaccine candidates for chikungunya. Vaccine. 26:5030–5039. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Hallengärd D, Kakoulidou M, Lulla A, Kümmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, et al: Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol. 88:2858–2866. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Chattopadhyay A, Wang E, Seymour R, Weaver SC and Rose JK: A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol. 87:395–402. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, et al: Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 7(e1002142)2011.PubMed/NCBI View Article : Google Scholar | |
|
Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE Jr and Lupton HW: Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine. 4:157–162. 1986.PubMed/NCBI View Article : Google Scholar | |
|
Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG and Mangiafico JA: Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 62:681–685. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Kushnir N, Streatfield SJ and Yusibov V: Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine. 31:58–83. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B and Tangy F: Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: A randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 15:519–527. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, Pfeiffer A, Muellner M, Tauber E and Ramsauer K: Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet. 392:2718–2727. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, et al: Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial. Lancet. 384:2046–2052. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Brandler S, Ruffié C, Combredet C, Brault JB, Najburg V, Prevost MC, Habel A, Tauber E, Desprès P and Tangy F: A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine. 31:3718–3725. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Weinbren M, Haddow AJ and Williams M: The occurrence of chikungunya virus in Uganda. I. Isolation from mosquitoes. Trans R Soc Trop Med Hyg. 52:253–262. 1958.PubMed/NCBI View Article : Google Scholar | |
|
Halstead SB and Buescher EL: Hemorrhagic disease in rodents infected with virus associated with Thai hemorrhagic fever. Science. 134:475–476. 1961.PubMed/NCBI View Article : Google Scholar | |
|
Shah KV, Gibbs CJ and Banerjee G: Virological investigation of the epidemic of haemorrhagic fever in Calcutta: Isolation of three strains of chikungunya virus. Indian J Med Res. 52:676–683. 1964.PubMed/NCBI | |
|
Liu H, Fang G, Wu H, Li Z and Ye Q: L-cysteine production in Escherichia coli based on rational metabolic engineering and modular strategy. Biotechnol J. 13(1700695)2018.PubMed/NCBI View Article : Google Scholar | |
|
Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG and Rao S: A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med. 16:334–338. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Saraswat S, Athmaram TN, Parida M, Agarwal A, Saha A and Dash PK: Expression and characterization of yeast derived chikungunya virus like particles (CHIK-VLPs) and its evaluation as a potential vaccine candidate. PLoS Negl Trop Dis. 10(e0004782)2016.PubMed/NCBI View Article : Google Scholar | |
|
Wang E, Petrakova O, Adams AP, Aguilar PV, Kang W, Paessler S, Volk SM, Frolov I and Weaver SC: Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. Vaccine. 25:7573–7581. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Van Den Doel P, Volz A, Roose JM, Sewbalaksing VD, Pijlman GP, van Middelkoop I, Duiverman V, van de Wetering E, Sutter G, Osterhaus AD and Martina BE: Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of chikungunya virus protects AG129 mice against lethal challenge. PLoS Negl Trop Dis. 8(e3101)2014.PubMed/NCBI View Article : Google Scholar | |
|
Weger-Lucarelli J, Chu H, Aliota MT, Partidos CD and Osorio JE: A novel MVA vectored chikungunya virus vaccine elicits protective immunity in mice. PLoS Negl Trop Dis. 8(e2970)2014.PubMed/NCBI View Article : Google Scholar | |
|
García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓS, Kümmerer BM, Liljeström P and Esteban M: A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol. 88:3527–3547. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, Luo M, Le TT, Anraku I, Sakalian M, Einfeld D and Dong JY: A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine. 29:2803–2809. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Kumar M, Sudeep AB and Arankalle VA: Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine. 30:6142–6149. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Khan M, Dhanwani R, Rao PVL and Parida M: Subunit vaccine formulations based on recombinant envelope proteins of chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res. 167:236–246. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, Partidos CD and Osorio JE: Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine. 31:3353–3360. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Malinoski FJ, Ksiazek T, Ramsburg H, Lupton HW and Meadors GF (eds): Safety and immunogenicity of a new chikungunya virus vaccine: double-blind, placebo controlled human trial. 38th Annual Meeting of the Amer Soc Trop Med Hyg, Section 8.2, 1989. | |
|
Chen P, Demirji J, Ivleva VB, Horwitz J, Schwartz R and Arnold F: The transient expression of CHIKV VLP in large stirred tank bioreactors. Cytotechnology. 71:1079–1093. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Chen GL, Coates EE, Plummer SH, Carter CA, Berkowitz N, Conan-Cibotti M, Cox JH, Beck A, O'Callahan M, Andrews C, et al: Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: A randomized clinical trial. JAMA. 323:1369–1377. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT and Osorio JE: Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine. 30:4638–4643. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, Raetz JL, Baker DC, Powers AM and Bowen RA: Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine. 25:1868–1876. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Sharma A and Knollmann-Ritschel B: Current understanding of the molecular basis of Venezuelan equine encephalitis virus pathogenesis and vaccine development. Viruses. 11(164)2019.PubMed/NCBI View Article : Google Scholar | |
|
Howley PM, Knipe DM and Whelan S: Fields virology: Emerging viruses. Lippincott Williams & Wilkins, 2020. | |
|
Weaver SC, Pfeffer M, Marriott K, Kang W and Kinney RM: Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks. Am J Trop Med Hyg. 60:441–448. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Chosewood LC and Wilson DE: Centers for disease control and prevention: Biosafety in microbiological and biomedical laboratories, US Department of Health and Human Services. Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health, Washington, DC, 2009. | |
|
Lundberg L, Carey B and Kehn-Hall K: Venezuelan equine encephalitis virus capsid-the clever caper. Viruses. 9(279)2017.PubMed/NCBI View Article : Google Scholar | |
|
Berge TO, Banks IS and Tigertt WD: Attenua-lion of Venezuelan equine encephalomyelitis virus by ire vitro cultivation in guinea-pig heart cells. Am J Hyg. 73:209–218. 1961. | |
|
Paessler S and Weaver SC: Vaccines for Venezuelan equine encephalitis. Vaccine. 27 (Suppl 4):D80–D85. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Cole FE Jr, May SW and Robinson DM: Formalin-inactivated Venezuelan equine encephalomyelitis (Trinidad strain) vaccine produced in rolling-bottle cultures of chicken embryo cells. Appl Microbiol. 25:262–265. 1973.PubMed/NCBI View Article : Google Scholar | |
|
Kinney RM, Tsuchiya KR, Sneider JM and Trent DW: Molecular evidence for the origin of the widespread Venezuelan equine encephalitis epizootic of 1969 to 1972. J Gen Virol. 73:3301–3305. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Kinney RM, Johnson BJ, Welch JB, Tsuchiya KR and Trent DW: The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology. 170:19–30. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH and Peters CJ: Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 14:337–343. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Rayfield E, Gorelkin L, Cumow R and Jahrling P: Virus-induced pancreatid disease induced by Venezuelan equine encephalitis virus. Alterations in glucose tolerance and insulin release. J Am Diab Assoc. 25:621–623. 1976.PubMed/NCBI View Article : Google Scholar | |
|
Sharma A, Raviv Y, Puri A, Viard M, Blumenthal R and Maheshwari RK: Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys Res Commun. 358:392–398. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Sharma A, Gupta P, Glass PJ, Parker MD and Maheshwari RK: Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: Implication in vaccine development. Vaccine. 29:953–959. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Gupta P, Sharma A, Spurgers KB, Bakken RR, Eccleston LT, Cohen JW, Honnold SP, Glass PJ and Maheshwari RK: 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus. Vaccine. 34:2762–2765. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK and Fine DL: Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine. 28:1031–1040. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Fine DL, Jenkins E, Martin SS, Glass P, Parker MD and Grimm B: A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV). J Virol Methods. 163:424–432. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Gaidamakova EK, Myles IA, McDaniel DP, Fowler CJ, Valdez PA, Naik S, Gayen M, Gupta P, Sharma A, Glass PJ, et al: Preserving immunogenicity of lethally irradiated viral and bacterial vaccine epitopes using a radio-protective Mn2+-peptide complex from Deinococcus. Cell Host Microbe. 12:117–124. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Gayen M, Gupta P, Morazzani EM, Gaidamakova EK, Knollmann-Ritschel B, Daly MJ, Glass PJ and Maheshwari RK: Deinococcus Mn2+-peptide complex: A novel approach to alphavirus vaccine development. Vaccine. 35:3672–3681. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Paessler S, Fayzulin RZ, Anishchenko M, Greene IP, Weaver SC and Frolov I: Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J Virol. 77:9278–9286. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Paessler S, Ni H, Petrakova O, Fayzulin RZ, Yun N, Anishchenko M, Weaver SC and Frolov I: Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J Virol. 80:2784–2796. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Erasmus JH, Seymour RL, Kaelber JT, Kim DY, Leal G, Sherman MB, Frolov I, Chiu W, Weaver SC and Nasar F: Novel insect-specific eilat virus-based chimeric vaccine candidates provide durable, mono-and multivalent, single-dose protection against lethal alphavirus challenge. J Virol. 92:e01274–17. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Hu WG, Steigerwald R, Kalla M, Volkmann A, Noll D and Nagata LP: Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses. Vaccine. 36:5194–5203. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Kafai NM, Williamson LE, Binshtein E, Sukupolvi-Petty S, Gardner CL, Liu J, Mackin S, Kim AS, Kose N, Carnahan RH, et al: Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge. J Exp Med. 219(e20212532)2022.PubMed/NCBI View Article : Google Scholar | |
|
Dupuy LC, Richards MJ, Reed DS and Schmaljohn CS: Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine. 28:7345–7350. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Lee J, Arun Kumar S, Jhan YY and Bishop CJ: Engineering DNA vaccines against infectious diseases. Acta Biomater. 80:31–47. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Dupuy LC, Locher CP, Paidhungat M, Richards MJ, Lind CM, Bakken R, Parker MD, Whalen RG and Schmaljohn CS: Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine. 27:4152–4160. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Tretyakova I, Lukashevich IS, Glass P, Wang E, Weaver S and Pushko P: Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. Vaccine. 31:1019–1025. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Rico AB, Phillips AT, Schountz T, Jarvis DL, Tjalkens RB, Powers AM and Olson KE: Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology. 499:30–39. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ni H, Yun NE, Zacks MA, Weaver SC, Tesh RB, Da Rosa APT, Powers AM, Frolov I and Paessler S: Recombinant alphaviruses are safe and useful serological diagnostic tools. Am J Trop Med Hyg. 76:774–781. 2007.PubMed/NCBI | |
|
Liljeström P and Garoff H: A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y). 9:1356–1361. 1991.PubMed/NCBI View Article : Google Scholar | |
|
Konopka JL, Thompson JM, Whitmore AC, Webb DL and Johnston RE: Acute infection with Venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge. J Virol. 83:12432–12442. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Grieder FB, Davis BK, Zhou XD, Chen SJ, Finkelman FD and Gause WC: Kinetics of cytokine expression and regulation of host protection following infection with molecularly cloned Venezuelan equine encephalitis virus. Virology. 233:302–312. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Phillpotts RJ, O'brien L, Appleton RE, Carr S and Bennett A: Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine. 23:1615–1623. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Phillpotts RJ, Jones LD and Howard SC: Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine. 20:1497–1504. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Parker MD, Buckley MJ, Melanson VR, Glass PJ, Norwood D and Hart MK: Antibody to the E3 glycoprotein protects mice against lethal Venezuelan equine encephalitis virus infection. J Virol. 84:12683–12690. 2010.PubMed/NCBI View Article : Google Scholar | |
|
O'Brien LM, Underwood-Fowler CD, Goodchild SA, Phelps AL and Phillpotts RJ: Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains. Virol J. 6(206)2009.PubMed/NCBI View Article : Google Scholar | |
|
Alevizatos AC, McKinney RW and Feigin RD: Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man. Am J Trop Med Hyg. 16:762–768. 1967.PubMed/NCBI | |
|
Pedersen CE Jr, Robinson DM and Cole FE Jr: Isolation of the vaccine strain of Venezuelan equine encephalomyelitis virus from mosquitoes in Louisiana. Am J Epidemiol. 95:490–496. 1972.PubMed/NCBI View Article : Google Scholar | |
|
Erwin-Cohen R, Porter A, Pittman P, Rossi C and Dasilva L: Host responses to live-attenuated Venezuelan equine encephalitis virus (TC-83): Comparison of naïve, vaccine responder and nonresponder to TC-83 challenge in human peripheral blood mononuclear cells. Hum Vaccin Immunother. 8:1053–1065. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Grieder FB, Davis NL, Aronson JF, Charles PC, Sellon DC, Suzuki K and Johnston RE: Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology. 206:994–1006. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Davis NL, Powell N, Greenwald GF, Willis LV, Johnson BJ, Smith JF and Johnston RE: Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: Construction of single and multiple mutants in a full-length cDNA clone. Virology. 183:20–31. 1991.PubMed/NCBI View Article : Google Scholar | |
|
Edelman R, Ascher MS, Oster CN, Ramsburg HH, Cole FE and Eddy GA: Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). J Infect Dis. 140:708–715. 1979.PubMed/NCBI View Article : Google Scholar | |
|
Johnson DM: Development of rationally designed live attenuated vaccines for Lassa fever and Venezuelan equine encephalitis. Electron Theses Diss. (3393)2020. | |
|
Hannaman D, Dupuy LC, Ellefsen B and Schmaljohn CS: A phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation. Vaccine. 34:3607–3612. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Powell LA, Miller A, Fox JM, Kose N, Klose T, Kim AS, Bombardi R, Tennekoon RN, Dharshan de Silva A, Carnahan RH, et al: Human mAbs broadly protect against arthritogenic alphaviruses by recognizing conserved elements of the Mxra8 receptor-binding site. Cell Host Microbe. 28:699–711.e7. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Tupanceska D, Zaid A, Rulli NE, Thomas S, Lidbury B, Matthaei K, Ramirez R and Mahalingam S: Ross River virus: An arthritogenic alphavirus of significant importance in the asia pacific. In: Lal SK (ed). Emerging viral diseases of Southeast Asia. Vol. 4. Issues Infect Dis. Basel, Karger, pp94-111, 2007. | |
|
Claflin SB and Webb CE: Ross River virus: Many vectors and unusual hosts make for an unpredictable pathogen. PLoS Pathog. 11(e1005070)2015.PubMed/NCBI View Article : Google Scholar | |
|
Earnest JT, Basore K, Roy V, Bailey AL, Wang D, Alter G, Fremont DH and Diamond MS: Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity. J Exp Med. 216:2282–2301. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, et al: Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell. 163:1095–1107. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Holzer GW, Coulibaly S, Aichinger G, Savidis-Dacho H, Mayrhofer J, Brunner S, Schmid K, Kistner O, Aaskov JG, Falkner FG, et al: Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine. 29:4132–4141. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, et al: Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial. Vaccine. 29:9376–9384. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Strauss JH and Strauss EG: The alphaviruses: Gene expression, replication, and evolution. Microbiol Rev. 58:491–562. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Ljungberg K and Liljeström P: Self-replicating alphavirus RNA vaccines. Expert Rev Vaccines. 14:177–194. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Frolov I, Hoffman TA, Prágai BM, Dryga SA, Huang HV, Schlesinger S and Rice CM: Alphavirus-based expression vectors: Strategies and applications. Proc Natl Acad Sci USA. 93:11371–11377. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C, et al: Vaccination of chimpanzees against infection by the hepatitis C virus. Vaccination of chimpanzees against infection by the hepatitis C virus USA. 91:1294–1298. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Lópex-Días de Cerio AL, Casares N, Lasarte JJ, Sarobe P, Pérez-Mediavilla LA, Ruiz M, Prieto J and Borrás-Cuesta F: T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. Int Immunol. 11:2025–2034. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Shirai M, Akatsuka T, Pendleton CD, Houghten R, Wychowski C, Mihalik K, Feinstone S and Berzofsky JA: Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J Virol. 66:4098–4106. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Leitner WW, Ying H and Restifo NP: DNA and RNA-based vaccines: Principles, progress and prospects. Vaccine. 18:765–777. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, Greenberg HB, Ito S and Liang TJ: Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology. 117:1397–1407. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Makimura M, Miyake S, Akino N, Takamori K, Matsuura Y, Miyamura T and Saito I: Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine. 14:28–36. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Brinster C and Inchauspé G: DNA vaccines for hepatitis C virus. Intervirology. 44:143–153. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, et al: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:69–74. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW and Restifo NP: Cancer therapy using a self-replicating RNA vaccine. Nat Med. 5:823–827. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Berglund P, Fleeton MN, Smerdou C and Liljeström P: Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine. 17:497–507. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Fleeton MN, Liljeström P, Sheahan BJ and Atkins GJ: Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol. 81:749–758. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Ajbani SP, Velhal SM, Kadam RB, Patel VV and Bandivdekar AH: Immunogenicity of Semliki Forest virus based self-amplifying RNA expressing Indian HIV-1C genes in mice. Int J Biol Macromol. 81:794–802. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Van De Wall S, Ljungberg K, IP PP, Boerma A, Nijman HW, Liljeström P and Daemen T: Development of a next generation Semliki Forest virus-based DNA vaccine against cervical cancer. Hum Gene Ther. 25(A30)2014. | |
|
Mussgay M and Weiland E: Preparation of inactivated vaccines against alphaviruses using Semliki Forest virus-white mouse as a model. I. Inactivation experiments and evaluation of double inactivated subunit vaccines. Intervirology. 1:259–268. 1973.PubMed/NCBI View Article : Google Scholar | |
|
Brinster C, Chen M, Boucreux D, Paranhos-Baccala G, Liljeström P, Lemmonier F and Inchauspé G: Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol. 83:369–381. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Oñate AA, Donoso G, Moraga-Cid G, Folch H, Céspedes S and Andrews E: An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun. 73:3294–3300. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Jiang X and Baldwin CL: Effects of cytokines on intracellular growth of Brucella abortus. Infect Immun. 61:124–134. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Jones SM and Winter AJ: Survival of virulent and attenuated strains of Brucella abortus in normal and gamma interferon-activated murine peritoneal macrophages. Infect Immun. 60:3011–3014. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Stevens MG, Pugh GW Jr and Tabatabai LB: Effects of gamma interferon and indomethacin in preventing Brucella abortus infections in mice. Infect Immun. 60:4407–4409. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Zhan Y and Cheers C: Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun. 61:4899–4901. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Ko J and Splitter GA: Molecular host-pathogen interaction in brucellosis: Current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev. 16:65–78. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Muñoz-Montesino C, Andrews E, Rivers R, González-Smith A, Moraga-Cid G, Folch H, Céspedes S and Oñate AA: Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect Immun. 72:2081–2087. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Colmenero P, Berglund P, Kambayashi T, Biberfeld P, Liljeström P and Jondal M: Recombinant Semliki Forest virus vaccine vectors: The route of injection determines the localization of vector RNA and subsequent T cell response. Gene Ther. 8:1307–1314. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Smerdou C and Liljestrom P: Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol. 73:1092–1098. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R and Liljeström P: Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses. 13:1487–1495. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Chen M, Hu KF, Rozell B, Örvell C, Morein B and Liljeström P: Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol. 169:3208–3216. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Singh A, Koutsoumpli G, van de Wall S and Daemen T: An alphavirus-based therapeutic cancer vaccine: From design to clinical trial. Cancer Immunol Immunother. 68:849–859. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Daemen T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A and Wilschut J: Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: Effects of the route of immunization. Antivir Ther. 9:733–742. 2004.PubMed/NCBI | |
|
Komdeur FL, Singh A, van de Wall S, Meulenberg JJM, Boerma A, Hoogeboom BN, Paijens ST, Oyarce C, de Bruyn M, Schuuring E, et al: First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers. Mol Ther. 29:611–625. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Vignuzzi M, Gerbaud S, van der Werf S and Escriou N: Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J Gen Virol. 82:1737–1747. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Brand D, Lemiale F, Turbica I, Buzelay L, Brunet S and Barin F: Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res Hum Retroviruses. 14:1369–1377. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M and Liljeström P: Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine. 12:1510–1514. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Johansson DX, Ljungberg K, Kakoulidou M and Liljeström P: Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One. 7(e29732)2012.PubMed/NCBI View Article : Google Scholar | |
|
Phenix KV, Wark K, Luke CJ, Skinner MA, Smyth JA, Mawhinney KA and Todd D: Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development. Vaccine. 19:3116–3123. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Goo J, Jeong Y, Park YS, Yang E, Jung DI, Rho S, Park U, Sung H, Park PG, Choi JA, et al: Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein. Virus Res. 278(197863)2020.PubMed/NCBI View Article : Google Scholar | |
|
Heinz FX, Holzmann H, Essl A and Kundi M: Field effectiveness of vaccination against tick-borne encephalitis. Vaccine. 25:7559–7567. 2007.PubMed/NCBI View Article : Google Scholar |
